LFMD Investors Have Opportunity to Lead LifeMD, Inc. Securities Fraud Lawsuit First Filed by The Rosen Law Firm
NEW YORK, Sept. 16, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of LifeMD, Inc. (NASDAQ: LFMD) between May 7, 2025 and August 5, 2025, both dates inclusive (the “Class Period”), of the important October 27, 2025 lead plaintiff deadline in the securities class action first […]
Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation
TOKYO, Sept. 16, 2025 /PRNewswire/ — Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that etalanetug (development code: E2814), an investigational anti-MTBR (microtubule binding region) tau antibody, was granted Fast Track designation by the U.S. Food and Drug Administration (FDA). Fast Track designation is an FDA program that is intended to facilitate […]
SOC Investors Have Opportunity to Lead Sable Offshore Corp. Securities Lawsuit Filed by The Rosen Law Firm
NEW YORK, Sept. 16, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sable Offshore Corp. (NYSE: SOC): (1) between May 19, 2025 and June 3, 2025, both dates inclusive (the “Class Period”); and/or (2) pursuant and/or traceable to Sable’s May 21, 2025 secondary public offering […]
Ascletis Presented Results from Cohorts 1 and 2 of 28-day Multiple Ascending Dose Study of Its Oral Small Molecule GLP-1R Agonist ASC30 at the 61st European Association for the Study of Diabetes (EASD) Annual Meeting
– ASC30 once-daily oral tablet demonstrated up to 6.5% placebo-adjusted mean body weight reduction from baseline after 28-day treatment. – ASC30 tablet’s higher efficacy is supported by its higher oral drug exposures. – ASC30 is safe and well tolerated with only mild-to-moderate gastrointestinal (GI) adverse events (AEs). There was no vomiting incidence in multiple ascending […]
Rosen Law Firm Encourages Encompass Health Corporation Investors to Inquire About Securities Class Action Investigation – EHC
NEW YORK, Sept. 16, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Encompass Health Corporation (NYSE: EHC) resulting from allegations that Encompass Health may have issued materially misleading business information to the investing public. So what: If you […]
LMT Investors Have Opportunity to Lead Lockheed Martin Corporation Securities Fraud Lawsuit
NEW YORK, Sept. 16, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Lockheed Martin Corporation (NYSE: LMT) between January 23, 2024 and July 21, 2025, both dates inclusive (the “Class Period”), of the important September 26, 2025 lead plaintiff deadline. So what: If you purchased […]
StubHub Announces Pricing of Initial Public Offering
NEW YORK, Sept. 16, 2025 /PRNewswire/ — StubHub Holdings, Inc. (“StubHub”), a leading global secondary ticketing marketplace for live events, today announced the pricing of its initial public offering of 34,042,553 shares of its Class A common stock at a public offering price of $23.50 per share. In addition, StubHub has granted the underwriters a […]
SVRA Investors have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit
NEW YORK, Sept. 16, 2025 /PRNewswire/ — Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Savara Inc. (NASDAQ: SVRA) between March 7, 2024 and May 23, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already […]
Clorox Declares Regular Quarterly Dividend of $1.24 Per Share
OAKLAND, Calif., Sept. 16, 2025 /PRNewswire/ — The Clorox Company (NYSE: CLX) announced today that its board of directors has declared a quarterly dividend of $1.24 per share on the company’s common stock. The dividend is payable November 6, 2025, to shareholders of record as of the close of business on October 22, 2025. Clorox has […]
NobleStitch™ Suture-Mediated PFO Closure Demonstrates Superior Long-Term Safety and Outcomes in Largest Cohort to Date
New data show zero device-related complications or atrial fibrillation, no recurrent stroke or TIA, with a cohort 40% larger than Gore and Amplatzer device studies FOUNTAIN VALLEY, Calif., Sept. 16, 2025 /PRNewswire/ — NobleStitch™, the deviceless suture-mediated patent foramen ovale (PFO) closure system distributed worldwide by HeartStitch, Inc., today announces robust long-term clinical results from […]